Cliff Asness's IOVA Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 3.87 M shares of Iovance Biotherapeutics, Inc. (IOVA) worth $16.1 M, representing 0.01% of the portfolio. First purchased in 2018-Q2, this long-term strategic position has been held for 25 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in IOVA, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2026, adding 3.25 M shares. Largest reduction occurred in Q3 2025, reducing 130,259 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Iovance Biotherapeutics (IOVA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Iovance Biotherapeutics (IOVA) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +3.25 M | Add 519.96% | 3.87 M | $4.16 |
| Q1 2026 | +513,577 | Add 464.39% | 624,168 | $3.51 |
| Q4 2025 | +9,193 | Add 9.07% | 110,591 | $2.73 |
| Q3 2025 | -130,259 | Reduce 56.23% | 101,398 | $2.17 |
| Q2 2025 | +172,117 | Add 289.08% | 231,657 | $1.72 |
| Q1 2025 | +43,829 | Add 278.97% | 59,540 | $3.28 |
| Q4 2024 | +15,711 | New Buy | 15,711 | $7.26 |
| Q3 2024 | -11,477 | Sold Out | 0 | $0.00 |
| Q2 2024 | -28,534 | Reduce 71.32% | 11,477 | $8.02 |
| Q1 2024 | +40,011 | New Buy | 40,011 | $14.57 |
| Q2 2023 | -84,325 | Sold Out | 0 | $0.00 |
| Q1 2023 | +34,576 | Add 69.50% | 84,325 | $6.11 |
| Q4 2022 | +49,749 | New Buy | 49,749 | $6.20 |
| Q2 2021 | -34,022 | Sold Out | 0 | $0.00 |
| Q1 2021 | -5,077 | Reduce 12.98% | 34,022 | $31.10 |
| Q4 2020 | +8,689 | Add 28.57% | 39,099 | $46.40 |
| Q3 2020 | -79,292 | Reduce 72.28% | 30,410 | $32.46 |
| Q2 2020 | +42,489 | Add 63.22% | 109,702 | $27.45 |
| Q1 2020 | +24,361 | Add 56.85% | 67,213 | $29.93 |
| Q4 2019 | +17,655 | Add 70.07% | 42,852 | $27.68 |
| Q3 2019 | +25,197 | New Buy | 25,197 | $18.22 |
| Q1 2019 | -33,573 | Sold Out | 0 | $0.00 |
| Q4 2018 | -13,119 | Reduce 28.10% | 33,573 | $8.85 |
| Q3 2018 | +7,293 | Add 18.51% | 46,692 | $11.24 |
| Q2 2018 | +39,399 | New Buy | 39,399 | $12.79 |
Cliff Asness's Iovance Biotherapeutics Investment FAQs
Cliff Asness first purchased Iovance Biotherapeutics, Inc. (IOVA) in Q2 2018, acquiring 39,399 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Iovance Biotherapeutics, Inc. (IOVA) for 25 quarters since Q2 2018.
Cliff Asness's largest addition to Iovance Biotherapeutics, Inc. (IOVA) was in Q2 2026, adding 3,869,584 shares worth $16.1 M.
According to the latest 13F filing for Q2 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 3,869,584 shares of Iovance Biotherapeutics, Inc. (IOVA), valued at approximately $16.1 M.
As of the Q2 2026 filing, Iovance Biotherapeutics, Inc. (IOVA) represents approximately 0.01% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Iovance Biotherapeutics, Inc. (IOVA) was 3,869,584 shares, as reported at the end of Q2 2026.